Aegerion Pharmaceuticals, Inc.
http://www.aegerion.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aegerion Pharmaceuticals, Inc.
CTAD 2023: Medical Centers Adapt To Leqembi Testing, Monitoring Requirements
Neurologists shared their health care facilities’ protocols as they begin treating Alzheimer’s patients with the first anti-amyloid treatment to win both US FDA approval and Medicare coverage – Eisai/Biogen’s Leqembi.
ESMO 23: Kelun/Merck, Hansoh ADCs Impress With Early Data In Breast Cancer
In new data from Chinese developers at ESMO, Kelun/Merck’s Trop2-targeting ADC SKB264 (MK-2870) appears ready to hog the limelight from Daiichi Sankyo/AstraZeneca’s Dato-DXd, while Hansoh’s B7-H4-targeting HS-20089 is coming to the fore against its global same-class competitors. There were also new clinical results for Mabwell/Hengrui’s Nectin-4-targeting 9MW2821 and HER2-targeting SHR-A1811.
News We’re Watching: Free COVID-19 Tests, Edwards Antitrust Investigation, McKinsey Calls For Medtech ‘Reinvention’
This week, the US government relaunched a program providing free COVID-19 tests and invested $600m in domestic test manufacturing; the European Commission revealed an antitrust investigation of Edwards LifeSciences; and a consulting firm report said the medtech industry should make big changes to address investor skepticism.
Deal Watch: Leo Pharma Adds Rare Dermatology Disorder Candidate In Timber Buyout
Plus deals involving SK Biopharmaceuticals, Hikma and Proteovant, Day One/Sprint, Eyenovia/Formosa, Clinigen/CNX, Ikena/Pionyr and more.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice